{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-066403","form_type":"8-K","ticker":"NTLA","cik":"0001652130","company_name":"Intellia Therapeutics, Inc.","filed_at":"2025-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.211292+00:00","generated_at":"2026-05-22T04:41:01.791723+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Intellia Q1 net loss $114.3M, cash $707.1M; Phase 3 HAE enrollment on track","bullets":["Net loss $114.3M vs $107.4M in Q1 2024; collaboration revenue $16.6M down from $28.9M.","Cash, cash equivalents and marketable securities $707.1M as of March 31, 2025, down from $861.7M at Dec 31, 2024; expected to fund operations into H1 2027.","Phase 3 HAELO study for hereditary angioedema on track to complete enrollment in Q3 2025; BLA submission anticipated in H2 2026.","First patient dosed in Phase 3 MAGNITUDE-2 for ATTRv-PN; MAGNITUDE (ATTR-CM) enrollment ahead of projections.","RMAT designation granted for nex-z in ATTR-CM; longer-term Phase 1 data presentations planned for H2 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-066403","json":"https://secwatch.observer/filing/0000950170-25-066403.json","markdown":"https://secwatch.observer/filing/0000950170-25-066403.md","text":"https://secwatch.observer/filing/0000950170-25-066403.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1652130/000095017025066403/0000950170-25-066403-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1652130/000095017025066403/ntla-20250508.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T04:41:01.791723+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}